Abstract
ObjectivesTofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with inadequate responses to tumour necrosis factor inhibitors...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have